EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model

Amy C Shurtleff, John C Trefry, Sheri Dubey, Melek M E Sunay, Kenneth Liu, Ziqiang Chen, Michael Eichberg, Peter M Silvera, Steve A Kwilas iD, Jay W Hooper iD, Shannon Martin, Jakub K Simon und 2 weitere

Viruses · 28.02.2025 · 17 (3) · 341

DOI: 10.3390/v17030341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 28.02.2025. Verfasst von Amy C Shurtleff und 13 weiteren Autor:innen. Beteiligte Einrichtung: US Army Medical Research Institute of Infectious Diseases (USAMRIID), Porter Street, Fort Detrick, Frederick, MD 21702, USA. Hauptthemen laut MEDLINE: Hemorrhagic Fever, Ebola, Ebola Vaccines, Ebolavirus, Viral Envelope Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S Department of Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR), Defense Threat Reduction Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recombinant vesicular stomatitis virus-Zaire Ebolavirus envelope glycoprotein vaccine (rVSVΔG-ZEBOV-GP) was highly effective against Ebola virus disease in a ring vaccination trial conducted during the 2014–2016 outbreak in Guinea and is licensed by regulatory agencies including US FDA, EMA, and prequalified by WHO. Vaccination studies in a nonhuman primate (NHP) model guided initial dose selection for clinical trial evaluation. We summarize two dose-ranging studies with the clinical-grade rVSVΔG-ZEBOV-GP vaccine candidate to assess the impact of dose level on immune responses and efficacy in an NHP Ebola virus (EBOV) challenge model. Forty-six cynomolgus macaques were vaccinated with a wide range of rVSVΔG-ZEBOV-GP doses and challenged 42 days later intramuscularly with 1000 pfu EBOV. Vaccination with rVSVΔG-ZEBOV-GP induced relatively high levels of EBOV-specific IgG and neutralizing antibodies, measured using the same validated assays as used in rVSVΔG-ZEBOV-GP clinical trials. Similar responses were observed across dose groups from 1 × 108 to 1 × 102 pfu. A single vaccination conferred 98% protection from lethal intramuscular EBOV challenge across all dose groups. These results demonstrate that robust antibody titers are induced in NHPs across a wide range of rVSVΔG-ZEBOV-GP vaccine doses, correlating with high levels of protection against death from EBOV challenge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemorrhagic Fever, EbolaEbola VaccinesEbolavirusViral Envelope ProteinsImmunogenicity, VaccineAnimalsAntibodies, ViralMacaca fascicularisAntibodies, NeutralizingDisease Models, AnimalVaccinationVaccines, SyntheticFemaleMaleVaccine Efficacy

Stichwörter der Autor:innen

ERVEBOEbolavirusnonhuman primatesvaccinevesicular stomatitis virus

Substanzen

Ebola VaccinesAntibodies, ViralAntibodies, NeutralizingViral Envelope ProteinsVaccines, Synthetic

Autor:innen und Institutionen

  • US Army Medical Research Institute of Infectious Diseases (USAMRIID), Porter Street, Fort Detrick, Frederick, MD 21702, USA.
  • Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, USA.
  • NewLink Genetics Corp., Loop Dr #5100, Ames, IA 50010, USA.

ORCID-Profile: Steve A Kwilas, Jay W Hooper

Förderung

  • U.S Department of Health and Human Services (HHS)
  • Administration for Strategic Preparedness and Response (ASPR)
  • Defense Threat Reduction Agency
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Zitieren

APA

Shurtleff, A. C., Trefry, J. C., Dubey, S., Sunay, M. M. E., Liu, K., Chen, Z., Eichberg, M., Silvera, P. M., Kwilas, S. A., Hooper, J. W., Martin, S., Simon, J. K., Coller, B. G., & Monath, T. P. (2025). rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model. Viruses, 17(3), 341. https://doi.org/10.3390/v17030341

Vancouver

Shurtleff AC, Trefry JC, Dubey S, Sunay MME, Liu K, Chen Z, et al. rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model. Viruses. 2025;17(3):341. doi:10.3390/v17030341

BibTeX
@article{Shurtleff2025,
  author = {Shurtleff, Amy C and Trefry, John C and Dubey, Sheri and Sunay, Melek M E and Liu, Kenneth and Chen, Ziqiang and Eichberg, Michael and Silvera, Peter M and Kwilas, Steve A and Hooper, Jay W and Martin, Shannon and Simon, Jakub K and Coller, Beth-Ann G and Monath, Thomas P},
  title = {rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model},
  journal = {Viruses},
  year = {2025},
  volume = {17},
  number = {3},
  pages = {341},
  doi = {10.3390/v17030341}
}
Kostenlos starten →